

BRAND ACCESS

Marketplace Dynamics: Autoimmune

Marketplace Dynamics: Autoimmune assesses current and future access and prescribing landscapes for autoimmune drugs, supporting identification of opportunities and risks for brands.

- What level of influence do payers and organized providers have on access in the autoimmune drugs market?
- How will payer and organized provider management and contracting for branded autoimmune drugs evolve over the next two years, and how should companies prepare for these changes?
- How are payers responding to key events in the autoimmune drugs market, such as new approvals and updated clinical data?

Use **Marketplace Dynamics: Autoimmune** to:

- Closely monitor market evolution
- Identify and monitor access shifts across the payer and organized provider segments
- Assess/predict payers' current and future management of the autoimmune drugs market to facilitate development of effective strategies for inline/pipeline brand(s)
- Identify risks for brands, along with opportunities to improve access

Brand Access Influencers and Management Landscape—Autoimmune February	<ul style="list-style-type: none"> • Road map for improving access for branded autoimmune drugs in 2021 • Analysis of stakeholder approaches to prioritizing and managing the autoimmune drugs market • Payer use of reimbursement, cost sharing, and utilization management tactics to influence use and restrict access of the autoimmune drug market • Brand-specific line-of-therapy requirements across autoimmune indications • Evolving management strategies for brands on the medical benefit, and evolving site-of-care management • Role of PBMs and specialty pharmacies (SPs) on product selection, distribution, and management
Organized Provider Management and Evolving Payment Models—Autoimmune April	<ul style="list-style-type: none"> • Organized provider use of management tools and tactics to influence drug use and specialist treatment decisions • Brand-specific line-of-therapy requirements across autoimmune indications • Prevalence of alternative payment models, innovative financial incentives, and performance metrics, along with associated impacts on drug access
Contracting Trends and Insights—Autoimmune June	<ul style="list-style-type: none"> • Impact and prevalence of contracting in the autoimmune drugs market • Key contracting terms and success factors driving access gains for branded autoimmune drugs • Evolution of risk-based contracting agreements for branded autoimmune drugs
Outlook on Brand Access in 2024—Autoimmune August	<ul style="list-style-type: none"> • Evolution of access in the branded autoimmune drugs market • Predicted management tactics for autoimmune drugs at payers and organized providers by 2024 • Brand access predictions reflecting in-depth future scenarios with high likelihood of occurring

This product may also include relevant market alerts, real-time assessments of recent changes, or discussions of market events. EVERSANA reserves the right to change the timing and/or topics of its syndicated research publications.

Visit: www.EVERSANA.com Phone: 609.397.5282 Email: HSIclientservices@EVERSANA.com